

**REMARKS**

Upon entry of the Amendment, claims 14 to 27, 29 to 30, and 43 to 66 are pending in the application. The specification is amended. Claims 1 to 13, 28, and 31 to 42 are canceled. Claims 14 to 27 are withdrawn from consideration. Claims 14 to 17, 21 to 27, and 29 to 30 are amended. Claims 43 to 66 are new.

No new matter is added. Withdrawn claim 14 is amended for the purpose of a possible rejoinder thereof. Withdrawn claims 15 and 16 are amended, in view of the amendment to withdrawn claim 14. Withdrawn claims 21 to 27 are amended in view of the cancellation of claims 1 to 13. The specification supports the amendments to claims 29 and 30, such as on pages 7 to 9. The specification supports new claims 43 to 66, such as on pages 7 to 9. Entry of the amendment is respectfully requested.

**I. Election/Restriction**

Referring to pages 2 to 3 of the Office Action, the Examiner asserts that Groups XXXI, X, XI, and XII do not share the same technical feature.

Applicants respectfully submit that the examination of Groups XXXI, X, XI, and XII would not result in an unduly burdensome search. Example 4 of the present specification discloses that each of SEQ ID NO: 4, SEQ ID NO: 7, and SEQ ID NO: 10 differ from the amino acid sequence of SEQ ID NO: 1 by one amino acid.

**II. Specification**

The specification is objected to allegedly because of the use of improperly demarcated trademarks.

The specification is amended in an effort to refer to trademarks.

**III. Claim Rejections - 35 U.S.C. § 112**

(A) Claims 29 and 30 are rejected under 35 U.S.C. § 112, second paragraph, as allegedly being indefinite.

The Examiner asserts that the phrase “the same or substantially is indefinite the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1.”

Claims 29 and 30 are amended. Applicants respectfully submit that a person skilled in the art can understand the metes and bounds of claims 29 and 30, as presently recited.

(B) Claims 29 to 30 are rejected under 35 U.S.C. § 112, first paragraph, as allegedly failing to comply with the written description requirement.

The Examiner asserts that the specification fails to provide written description support for a protein having “substantially the same” amino acid sequence as the amino acid sequence of SEQ ID NO: 1 or the claimed partial peptide. The Examiner asserts that a person skilled in the art could not immediately envision, recognize or distinguish most of the members of the genus.

Applicants respectfully submit that the specification provides written description support to amended claims 29 and 30. Page 9 of the specification describes that the protein may have 1 to 10 substitutions, deletions, or insertions. Example 8 of the specification also describes producing antibodies with peptides having the amino acid sequence present at position 402 to 412 of SEQ ID NO: 1, 582 to 596 of SEQ ID NO: 1, 781 to 794 of SEQ ID NO: 1, and 797 to 809 of SEQ ID NO: 1. *See Example 8 of the Specification.* Further, the specification provides the amino acid sequences of SEQ ID NOs: 4, 7, and 10. SEQ ID NO: 4 differs from SEQ ID NO: 1 at position 208. SEQ ID NO: 7 differs from SEQ ID NO: 1 at position 163. SEQ ID NO: 10 differs from SEQ ID NO: 1 at position 364.

In view of the above descriptions, a person skilled in the art can predict the amino acid sequence of an amino acid sequence in which 1 to 10 amino acid sequences have been substituted, deleted or inserted into SEQ ID NO: 1, wherein said substitution, deletion, or insertion is with an amino acid position outside of position 402 to 412 of SEQ ID NO: 1, 582 to 596 of SEQ ID NO: 1, 781 to 794 of SEQ ID NO: 1, and 797 to 809 of SEQ ID NO: 1. The amino acid sequence indicates which positions may include the substitution, deletion, or insertions of 1 to 10 amino acids. Example 8 describes using peptides having the amino acids at positions 402 to 412, 582 to 596, 781 to 794, and 797 to 809 of SEQ ID NO: 1 to produce the antibodies thereof. The specification provides examples of such an amino acid sequence in SEQ ID NOS: 4, 7, and 10. In this regard, the specification provides written description support to amended claims 29 and 30.

#### **IV. Claim Rejections - 35 U.S.C. § 102**

The Office Action contains two rejections under 35 U.S.C. § 102, as follows:

claims 29 to 30 are rejected under 35 U.S.C. § 102(b) as allegedly being anticipate by Osada et al.; and

claims 29 and 30 are rejected under 35 U.S.C. § 102(b) as allegedly being anticipated by Cuello et al.

With respect to Osada, the Examiner asserts that Osada discloses an antiphosphotyrosine monoclonal antibody that specifically binds to phosphotyrosine amino acids. The Examiner asserts that SEQ ID NO: 1 includes multiple tyrosine residues.

Applicants respectfully submit that Osada fails to describe or suggest an antibody that specifically binds to the claimed proteins. Figure 2 of Osada indicates that the antiphosphotyrosine antibody thereof unspecifically binds to proteins including phosphotyrosine amino acids. In this regard, Figure 2 of Osada indicates that the antiphosphotyrosine antibody

thereof may bind to proteins that do not comprise the amino acid sequence of SEQ ID NO: 1 or to proteins in which one to ten amino acids have deleted from, inserted into, or substituted inot the amino acid sequence of SEQ ID NO: 1, wherein said deletion, insertion, or substitution occurs at an amino acid position outside of positions 402 to 412 of SEQ ID NO: 1, 582 to 596 of SEQ ID NO: 1, 781 to 794 of SEQ ID NO: 1, and 797 to 809 of SEQ ID NO: 1. More than a phosphotyrosine amino acid, if any, is present at positions 402 to 412, 582 to 596, 781 to 794, and 797 to 809 of SEQ ID NO: 1. In this regard, the antiphosphotyrosine antibody is not specific to the proteins recited in claims 29 and 30.

With respect to Cuello, the Examiner asserts that Cuello describes an antibody that binds to an erbB-2 polypeptide (i.e., trastuzumab). The Examiner asserts that the protein recited in claims 29 and 30 would encompass erbB-2 as disclosed in Cuello.

Applicants Cuello fails to expressly describe the amino acid sequence of the erbB-2 polypeptide thereof. Cuello discloses using erbB-2 from several cell lines (SKBr-3, MDA-MB-453, SKOv-3, MDA-MB-468, SW-626, MDA-MB-231, and MCF-7). *See* Cuello, p. 4892-4893. GENBANK™ provides the amino acid sequence of Receptor tyrosine-protein kinase erbB-2 precursor (p185erbB2). A copy of the amino acid sequence is provided herewith. Based on a comparison with the Receptor tyrosine-protein kinase erbB-2, it appears that amino acid sequences of the claimed proteins are significantly different. In this regard, the antibody disclosed in Cuello is different from the antibody recited in claims 29 and 30.

## V. Double Patenting

Claims 29-30 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting, as allegedly being unpatentable over claims 1-14 of copending Application no. 10/584,183.

Applicants defer responding at this time to this provisional obviousness-type double patenting rejection, pursuant to MPEP § 804(I)(B).

In view of the above, reconsideration and allowance of this application are now believed to be in order, and such actions are hereby solicited. If any points remain in issue which the Examiner feels may be best resolved through a personal or telephone interview, the Examiner is kindly requested to contact the undersigned at the telephone number listed below.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.


Respectfully submitted,

  
\_\_\_\_\_  
Michael R. Dzwonczyk  
Registration No. 36,787

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE  
**23373**  
CUSTOMER NUMBER

Date: October 18, 2007



My NC

[Sign In] [Regis]

[PubMed](#)   [Nucleotide](#)   [Protein](#)   [Genome](#)   [Structure](#)   [PMC](#)   [Taxonomy](#)   [OMIM](#)   [Books](#)

 Search **Protein** for   
[Limits](#)[Preview/Index](#)[History](#)[Clipboard](#)[Details](#)
 Display **GenPept** Show **5** 

 Range: from **begin** to **end** Features:  CDD 
**P04626:** P04626. Reports Receptor tyrosine...[gi:119533]

[BLink](#), [Conserved Domains](#), [Links](#)
Comment   Features   Sequence

**LOCUS** P04626 1255 aa linear PRI 10-JUL-2007  
**DEFINITION** Receptor tyrosine-protein kinase erbB-2 precursor (p185erbB2) (C-erbB-2) (NEU proto-oncogene) (Tyrosine kinase-type cell surface receptor HER2) (MLN 19) (CD340 antigen).  
**ACCESSION** P04626  
**VERSION** P04626 GI:119533  
**DBSOURCE** swissprot: locus ERBB2\_HUMAN, accession P04626; class: standard.  
extra accessions:Q14256,Q6LDV1,Q9UMK4  
created: Aug 13, 1987.  
sequence updated: Aug 13, 1987.  
annotation updated: Jul 10, 2007.  
xrefs: M11767.1, AAA35808.1, M11761.1, M11762.1, M11763.1, M11764.1, M11765.1, M11766.1, M11730.1, AAA75493.1, M12036.1, AAA35978.1, AY208911.1, AAO18082.1, X03363.1, CAA27060.1, M16792.1, AAA58637.1, M16789.1, M16790.1, M16791.1, L29395.1, AAA35809.1, M95667.1, AAC37531.1, A24571, 1N8ZC, 1OVC\_A, 1QR1F, 1S78A, 1S78B, 2A91A  
xrefs (non-sequence databases): UniGene:Hs.446352, DIP:DIP:8N, IntAct:P04626, Ensembl:ENSG00000141736, KEGG:hsa:2064, HGNC:3430, HPA:CAB000043, HPA:HPA001383, MIM: 164870, PharmGKB:PA27844, DrugBank:BTD00098, LinkHub:P04626, ArrayExpress:P04626, GermOnline:ENSG00000141736, RZPD-ProtExp:B0017, GO:0016021, GO:0005886, GO:0005006, GO:0043125, GO:0042802, GO:0046982, GO:0004716, GO:0007507, GO:0030879, GO:0007399, GO:0048015, GO:0050679, GO:0043406, GO:0006468, GO:0045765, GO:0007169, InterPro:IPR000494, InterPro:IPR006211, InterPro:IPR006212, InterPro:IPR000719, InterPro:IPR001245, InterPro:IPR008266, InterPro:IPR004019, Pfam:PF00757, Pfam:PF07714, Pfam:PF01030, Pfam:PF02757, PRINTS:PR00109, ProDom:PD000001, SMART:SM00261, SMART:SM00219, PROSITE:PS00107, PROSITE:PS50011, PROSITE:PS00109  
**KEYWORDS** 3D-structure; ATP-binding; Glycoprotein; Kinase; Membrane; Nucleotide-binding; Phosphorylation; Polymorphism; Receptor; Signal; Transferase; Transmembrane; Tyrosine-protein kinase.  
**SOURCE** Homo sapiens (human)  
**ORGANISM** Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; Homo.  
**REFERENCE** 1 (residues 1 to 1255)  
**AUTHORS** Yamamoto,T., Ikawa,S., Akiyama,T., Semba,K., Nomura,N., Miyajima,N., Saito,T. and Toyoshima,K.  
**TITLE** Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor  
**JOURNAL** Nature 319 (6050), 230-234 (1986)  
**PUBMED** 3003577

REMARK NUCLEOTIDE SEQUENCE [mRNA].  
REFERENCE 2 (residues 1 to 1255)  
AUTHORS Coussens,L., Yang-Feng,T.L., Liao,Y.C., Chen,E., Gray,A., McGrath,J., Seeburg,P.H., Libermann,T.A., Schlessinger,J., Francke,U., Levinson,A. and Ullrich,A.  
TITLE Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene  
JOURNAL Science 230 (4730), 1132-1139 (1985)  
PUBMED 2999974  
REMARK NUCLEOTIDE SEQUENCE [GENOMIC DNA / mRNA], AND VARIANT ALA-1170.  
REFERENCE 3 (residues 1 to 1255)  
AUTHORS Rieder,M.J., Livingston,R.J., Daniels,M.R., Montoya,M.A., Chung,M.-W., Miyamoto,K.E., Nguyen,C.P., Nguyen,D.A., Poel,C.L., Robertson,P.D., Schackwitz,W.S., Sherwood,J.K., Wittrak,L.A. and Nickerson,D.A.  
TITLE Direct Submission  
JOURNAL Submitted (??-DEC-2002)  
REMARK NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS CYS-452; VAL-655 AND ALA-1170.  
REFERENCE 4 (residues 1 to 1255)  
AUTHORS Tal,M., King,C.R., Kraus,M.H., Ullrich,A., Schlessinger,J. and Givol,D.  
TITLE Human HER2 (neu) promoter: evidence for multiple mechanisms for transcriptional initiation  
JOURNAL Mol. Cell. Biol. 7 (7), 2597-2601 (1987)  
PUBMED 3039351  
REMARK NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-191.  
REFERENCE 5 (residues 1 to 1255)  
AUTHORS Semba,K., Kamata,N., Toyoshima,K. and Yamamoto,T.  
TITLE A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma  
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 82 (19), 6497-6501 (1985)  
PUBMED 2995967  
REMARK NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 737-1031.  
REFERENCE 6 (residues 1 to 1255)  
AUTHORS King,C.R., Kraus,M.H. and Aaronson,S.A.  
TITLE Amplification of a novel v-erbB-related gene in a human mammary carcinoma  
JOURNAL Science 229 (4717), 974-976 (1985)  
PUBMED 2992089  
REMARK NUCLEOTIDE SEQUENCE OF 832-909.  
TISSUE=Mammary carcinoma  
REFERENCE 7 (residues 1 to 1255)  
AUTHORS Sarkar,F.H., Ball,D.E., Li,Y.W. and Crissman,J.D.  
TITLE Molecular cloning and sequencing of an intron of Her-2/neu (ERBB2) gene  
JOURNAL DNA Cell Biol. 12 (7), 611-615 (1993)  
PUBMED 8104414  
REMARK NUCLEOTIDE SEQUENCE OF 1081-1245, AND VARIANT ALA-1170.  
REFERENCE 8 (residues 1 to 1255)  
AUTHORS Arcaro,A., Zvelebil,M.J., Wallasch,C., Ullrich,A., Waterfield,M.D. and Domin,J.  
TITLE Class II phosphoinositide 3-kinases are downstream targets of activated polypeptide growth factor receptors  
JOURNAL Mol. Cell. Biol. 20 (11), 3817-3830 (2000)  
PUBMED 10805725  
REMARK IDENTIFICATION IN A COMPLEX WITH PIK3C2A AND EGFR, IDENTIFICATION IN A COMPLEX WITH PIK3C2B AND EGFR, AND INTERACTION WITH PIK3C2B.  
REFERENCE 9 (residues 1 to 1255)  
AUTHORS Swiercz,J.M., Kuner,R. and Offermanns,S.  
TITLE Plexin-B1/RhoGEF-mediated RhoA activation involves the receptor tyrosine kinase ErbB-2  
JOURNAL J. Cell Biol. 165 (6), 869-880 (2004)

PUBMED 15210733  
 REMARK INTERACTION WITH PLXNB1.  
 REFERENCE 10 (residues 1 to 1255)  
 AUTHORS Marone,R., Hess,D., Dankort,D., Muller,W.J., Hynes,N.E. and Badache,A.  
 TITLE Memo mediates ErbB2-driven cell motility  
 JOURNAL Nat. Cell Biol. 6 (6), 515-522 (2004)  
 PUBMED 15156151  
 REMARK INTERACTION WITH MEMO.  
 REFERENCE 11 (residues 1 to 1255)  
 AUTHORS Olsen,J.V., Blagoev,B., Gnad,F., Macek,B., Kumar,C., Mortensen,P. and Mann,M.  
 TITLE Global, in vivo, and site-specific phosphorylation dynamics in signaling networks  
 JOURNAL Cell 127 (3), 635-648 (2006)  
 PUBMED 17081983  
 REMARK PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1248, AND MASS SPECTROMETRY.  
 TISSUE=Epithelium  
 REFERENCE 12 (residues 1 to 1255)  
 AUTHORS Kuhns,J.J., Batalia,M.A., Yan,S. and Collins,E.J.  
 TITLE Poor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a lack of interactions with the center of the peptide  
 JOURNAL J. Biol. Chem. 274 (51), 36422-36427 (1999)  
 PUBMED 10593938  
 REMARK X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 654-662 IN COMPLEX WITH HLA AND BETA-2 MICROGLOBULIN.  
 REFERENCE 13 (residues 1 to 1255)  
 AUTHORS Cho,H.S., Mason,K., Ramyar,K.X., Stanley,A.M., Gabelli,S.B., Denney,D.W. Jr. and Leahy,D.J.  
 TITLE Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab  
 JOURNAL Nature 421 (6924), 756-760 (2003)  
 PUBMED 12610629  
 REMARK X-RAY CRYSTALLOGRAPHY (2.52 ANGSTROMS) OF 23-629 IN COMPLEX WITH FAB.  
 REFERENCE 14 (residues 1 to 1255)  
 AUTHORS Ehsani,A., Low,J., Wallace,R.B. and Wu,A.M.  
 TITLE Characterization of a new allele of the human ERBB2 gene by allele-specific competition hybridization  
 JOURNAL Genomics 15 (2), 426-429 (1993)  
 PUBMED 8095488  
 REMARK VARIANTS VAL-654 AND VAL-655.  
 COMMENT On Mar 15, 2005 this sequence version replaced gi:86984.  
 [FUNCTION] Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Not activated by EGF, TGF-alpha and amphiregulin.  
 [CATALYTIC ACTIVITY] ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.  
 [SUBUNIT] Heterodimer with each of the other ERBB receptors (Potential). Interacts with PRKCABP and PLXNB1. Part of a complex with EGFR and either PIK3C2A or PIK3C2B. May interact with PIK3C2B when phosphorylated on Tyr-1196. Interacts with MEMO when phosphorylated on Tyr-1248.  
 [INTERACTION] Self; NbExp=1; IntAct=EBI-641062, EBI-641062; P62157:CALM (xeno); NbExp=1; IntAct=EBI-641062, EBI-397403; P62161:Calm1 (xeno); NbExp=1; IntAct=EBI-641062, EBI-397530; P00533:EGFR; NbExp=2; IntAct=EBI-641062, EBI-297353; P21860:ERBB3; NbExp=4; IntAct=EBI-641062, EBI-720706; Q15303:ERBB4; NbExp=2; IntAct=EBI-641062, EBI-80371.  
 [SUBCELLULAR LOCATION] Membrane; Single-pass type I membrane protein.  
 [PTM] Ligand-binding increases phosphorylation on tyrosine residues

(By similarity).

[POLYMORPHISM] There are four alleles due to the variations in positions 654 and 655. Allele B1 (Ile-654/Ile-655) has a frequency of 0.782; allele B2 (Ile-654/Val-655) has a frequency of 0.206; allele B3 (Val-654/Val-655) has a frequency of 0.012.

[SIMILARITY] Belongs to the Tyr protein kinase family. EGF receptor subfamily.

[SIMILARITY] Contains 1 protein kinase domain.

[WEB RESOURCE] NAME=Atlas of Genetics and Cytogenetics in Oncology and Haematology;

URL='<http://atlasgeneticsoncology.org/Genes/ERBB2ID162ch17q11.html>'

[WEB RESOURCE] NAME=Wikipedia ERBB2 entry;  
URL='<http://en.wikipedia.org/wiki/ERBB2>'.

FEATURES Location/Qualifiers

source 1..1255  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"

gene 1..1255  
/gene="ERBB2"  
/note="synonyms: HER2, NEU, NGL"  
1..1255  
/gene="ERBB2"  
/product="Receptor tyrosine-protein kinase erbB-2 precursor"  
/EC\_number="2.7.10.1"

Region 1..22  
/gene="ERBB2"  
/region\_name="Signal"  
/inference="non-experimental evidence, no additional details recorded"  
/note="Potential."

Region 23..1255  
/gene="ERBB2"  
/region\_name="Mature chain"  
/experiment="experimental evidence, no additional details recorded"  
/note="Receptor tyrosine-protein kinase erbB-2.  
/FTId=PRO\_0000016669."

Region 23..652  
/gene="ERBB2"  
/region\_name="Topological domain"  
/inference="non-experimental evidence, no additional details recorded"  
/note="Extracellular (Potential)."

Region 25..27  
/gene="ERBB2"  
/region\_name="Beta-strand region"  
/experiment="experimental evidence, no additional details recorded"

Region 39..50  
/gene="ERBB2"  
/region\_name="Helical region"  
/experiment="experimental evidence, no additional details recorded"

Region 52..173  
/gene="ERBB2"  
/region\_name="Recep\_L\_domain"  
/note="Receptor L domain. The L domains from these receptors make up the bilobal ligand binding site. Each L domain consists of a single-stranded right hand beta-helix. This Pfam entry is missing the first 50 amino acid residues of the domain; pfam01030"  
/db\_xref="CDD:79745"

Region 55..64  
/gene="ERBB2"  
/region\_name="Beta-strand region"  
/experiment="experimental evidence, no additional details recorded"

Site 68  
/gene="ERBB2"  
/site\_type="glycosylation"  
/inference="non-experimental evidence, no additional details recorded"  
/note="N-linked (GlcNAc...) (Potential)."

Region 72..74  
/gene="ERBB2"  
/region\_name="Helical region"  
/experiment="experimental evidence, no additional details recorded"

Region 79..82  
/gene="ERBB2"  
/region\_name="Beta-strand region"  
/experiment="experimental evidence, no additional details recorded"

Region 84..88  
/gene="ERBB2"  
/region\_name="Beta-strand region"  
/experiment="experimental evidence, no additional details recorded"

Region 109..111  
/gene="ERBB2"  
/region\_name="Hydrogen bonded turn"  
/experiment="experimental evidence, no additional details recorded"

Region 112..117  
/gene="ERBB2"  
/region\_name="Beta-strand region"  
/experiment="experimental evidence, no additional details recorded"

Site 124  
/gene="ERBB2"  
/site\_type="glycosylation"  
/inference="non-experimental evidence, no additional details recorded"  
/note="N-linked (GlcNAc...) (Potential)."

Region 152..157  
/gene="ERBB2"  
/region\_name="Beta-strand region"  
/experiment="experimental evidence, no additional details recorded"

Region 164..166  
/gene="ERBB2"  
/region\_name="Hydrogen bonded turn"  
/experiment="experimental evidence, no additional details recorded"

Region 169..172  
/gene="ERBB2"  
/region\_name="Helical region"  
/experiment="experimental evidence, no additional details recorded"

Region 175..177  
/gene="ERBB2"  
/region\_name="Helical region"  
/experiment="experimental evidence, no additional details recorded"

Region 182..184  
/gene="ERBB2"

/region\_name="Beta-strand region"  
/experiment="experimental evidence, no additional details recorded"  
Site  
187  
/gene="ERBB2"  
/site\_type="glycosylation"  
/inference="non-experimental evidence, no additional details recorded"  
/note="N-linked (GlcNAc...) (Potential)."  
Region  
189..343  
/gene="ERBB2"  
/region\_name="Furin-like"  
/note="Furin-like cysteine rich region; pfam00757"  
/db\_xref="CDD:64613"  
Bond  
bond(195,204)  
/gene="ERBB2"  
/bond\_type="disulfide"  
/inference="non-experimental evidence, no additional details recorded"  
/note="By similarity."  
Bond  
bond(199,212)  
/gene="ERBB2"  
/bond\_type="disulfide"  
/inference="non-experimental evidence, no additional details recorded"  
/note="By similarity."  
Region  
199..202  
/gene="ERBB2"  
/region\_name="Beta-strand region"  
/experiment="experimental evidence, no additional details recorded"  
Region  
204..208  
/gene="ERBB2"  
/region\_name="Beta-strand region"  
/experiment="experimental evidence, no additional details recorded"  
Region  
217..219  
/gene="ERBB2"  
/region\_name="Beta-strand region"  
/experiment="experimental evidence, no additional details recorded"  
Bond  
bond(220,227)  
/gene="ERBB2"  
/bond\_type="disulfide"  
/inference="non-experimental evidence, no additional details recorded"  
/note="By similarity."  
Region  
221..223  
/gene="ERBB2"  
/region\_name="Beta-strand region"  
/experiment="experimental evidence, no additional details recorded"  
Bond  
bond(224,235)  
/gene="ERBB2"  
/bond\_type="disulfide"  
/inference="non-experimental evidence, no additional details recorded"  
/note="By similarity."  
Region  
227..231  
/gene="ERBB2"  
/region\_name="Beta-strand region"  
/experiment="experimental evidence, no additional details recorded"  
Region  
232..234

/gene="ERBB2"  
/region\_name="Helical region"  
/experiment="experimental evidence, no additional details recorded"  
Region  
235..280  
/gene="ERBB2"  
/region\_name="FU"  
/note="Furin-like repeats. Cysteine rich region. Exact function of the domain is not known. Furin is a serine-kinase dependent proprotein processor. Other members of this family include endoproteases and cell surface receptors; cd00064"  
/db\_xref="CDD:28946"  
Bond  
bond(236,244)  
/gene="ERBB2"  
/bond\_type="disulfide"  
/inference="non-experimental evidence, no additional details recorded"  
/note="By similarity."  
Bond  
bond(240,252)  
/gene="ERBB2"  
/bond\_type="disulfide"  
/inference="non-experimental evidence, no additional details recorded"  
/note="By similarity."  
Region  
240..242  
/gene="ERBB2"  
/region\_name="Beta-strand region"  
/experiment="experimental evidence, no additional details recorded"  
Region  
244..248  
/gene="ERBB2"  
/region\_name="Beta-strand region"  
/experiment="experimental evidence, no additional details recorded"  
Region  
251..260  
/gene="ERBB2"  
/region\_name="Beta-strand region"  
/experiment="experimental evidence, no additional details recorded"  
Bond  
bond(255,264)  
/gene="ERBB2"  
/bond\_type="disulfide"  
/inference="non-experimental evidence, no additional details recorded"  
/note="By similarity."  
Site  
259  
/gene="ERBB2"  
/site\_type="glycosylation"  
/inference="non-experimental evidence, no additional details recorded"  
/note="N-linked (GlcNAc...) (Potential)."  
Region  
263..267  
/gene="ERBB2"  
/region\_name="Beta-strand region"  
/experiment="experimental evidence, no additional details recorded"  
Bond  
bond(268,295)  
/gene="ERBB2"  
/bond\_type="disulfide"  
/inference="non-experimental evidence, no additional details recorded"  
/note="By similarity."  
Region  
271..274

Region  
276..278  
/gene="ERBB2"  
/region\_name="Beta-strand region"  
/experiment="experimental evidence, no additional details recorded"  
Region  
281..283  
/gene="ERBB2"  
/region\_name="Hydrogen bonded turn"  
/experiment="experimental evidence, no additional details recorded"  
Region  
289..291  
/gene="ERBB2"  
/region\_name="Beta-strand region"  
/experiment="experimental evidence, no additional details recorded"  
Region  
294..298  
/gene="ERBB2"  
/region\_name="Beta-strand region"  
/experiment="experimental evidence, no additional details recorded"  
Bond  
bond(299,311)  
/gene="ERBB2"  
/bond\_type="disulfide"  
/inference="non-experimental evidence, no additional details recorded"  
/note="By similarity."  
Region  
303..305  
/gene="ERBB2"  
/region\_name="Beta-strand region"  
/experiment="experimental evidence, no additional details recorded"  
Region  
309..314  
/gene="ERBB2"  
/region\_name="Beta-strand region"  
/experiment="experimental evidence, no additional details recorded"  
Bond  
bond(315,331)  
/gene="ERBB2"  
/bond\_type="disulfide"  
/inference="non-experimental evidence, no additional details recorded"  
/note="By similarity."  
Region  
319..323  
/gene="ERBB2"  
/region\_name="Beta-strand region"  
/experiment="experimental evidence, no additional details recorded"  
Region  
329..333  
/gene="ERBB2"  
/region\_name="Beta-strand region"  
/experiment="experimental evidence, no additional details recorded"  
Bond  
bond(334,338)  
/gene="ERBB2"  
/bond\_type="disulfide"  
/inference="non-experimental evidence, no additional details recorded"  
/note="By similarity."  
Region  
335..337  
/gene="ERBB2"

Region  
348..350  
*/gene="ERBB2"*  
*/region\_name="Beta-strand region"*  
*/experiment="experimental evidence, no additional details recorded"*

Region  
358..360  
*/gene="ERBB2"*  
*/region\_name="Helical region"*  
*/experiment="experimental evidence, no additional details recorded"*

Region  
361..364  
*/gene="ERBB2"*  
*/region\_name="Helical region"*  
*/experiment="experimental evidence, no additional details recorded"*

Region  
366..486  
*/gene="ERBB2"*  
*/region\_name="Recep\_L\_domain"*  
*/note="Receptor L domain. The L domains from these receptors make up the bilobal ligand binding site. Each L domain consists of a single-stranded right hand beta-helix. This Pfam entry is missing the first 50 amino acid residues of the domain; pfam01030"*  
*/db\_xref="CDD:79745"*

Region  
368..376  
*/gene="ERBB2"*  
*/region\_name="Beta-strand region"*  
*/experiment="experimental evidence, no additional details recorded"*

Region  
378..380  
*/gene="ERBB2"*  
*/region\_name="Helical region"*  
*/experiment="experimental evidence, no additional details recorded"*

Region  
396..402  
*/gene="ERBB2"*  
*/region\_name="Helical region"*  
*/experiment="experimental evidence, no additional details recorded"*

Region  
405..408  
*/gene="ERBB2"*  
*/region\_name="Beta-strand region"*  
*/experiment="experimental evidence, no additional details recorded"*

Region  
410..413  
*/gene="ERBB2"*  
*/region\_name="Beta-strand region"*  
*/experiment="experimental evidence, no additional details recorded"*

Region  
423..425  
*/gene="ERBB2"*  
*/region\_name="Helical region"*  
*/experiment="experimental evidence, no additional details recorded"*

Region  
438..440  
*/gene="ERBB2"*  
*/region\_name="Hydrogen bonded turn"*  
*/experiment="experimental evidence, no additional details recorded"*

Region  
441..447  
*/gene="ERBB2"*

Region  
452  
/gene="ERBB2"  
/region\_name="Variant"  
/experiment="experimental evidence, no additional details recorded"  
/note="W -> C. /FTId=VAR\_016317."  
Region  
463..469  
/gene="ERBB2"  
/region\_name="Beta-strand region"  
/experiment="experimental evidence, no additional details recorded"  
Region  
482..485  
/gene="ERBB2"  
/region\_name="Helical region"  
/experiment="experimental evidence, no additional details recorded"  
Region  
493..498  
/gene="ERBB2"  
/region\_name="Beta-strand region"  
/experiment="experimental evidence, no additional details recorded"  
Region  
501..506  
/gene="ERBB2"  
/region\_name="Helical region"  
/experiment="experimental evidence, no additional details recorded"  
Region  
509..544  
/gene="ERBB2"  
/region\_name="FU"  
/note="Furin-like repeats; smart00261"  
/db\_xref="CDD:47590"  
Bond  
bond(511,520)  
/gene="ERBB2"  
/bond\_type="disulfide"  
/inference="non-experimental evidence, no additional details recorded"  
/note="By similarity."  
Bond  
bond(515,528)  
/gene="ERBB2"  
/bond\_type="disulfide"  
/inference="non-experimental evidence, no additional details recorded"  
/note="By similarity."  
Region  
516..518  
/gene="ERBB2"  
/region\_name="Helical region"  
/experiment="experimental evidence, no additional details recorded"  
Region  
520..524  
/gene="ERBB2"  
/region\_name="Beta-strand region"  
/experiment="experimental evidence, no additional details recorded"  
Region  
528..536  
/gene="ERBB2"  
/region\_name="Beta-strand region"  
/experiment="experimental evidence, no additional details recorded"  
Site  
530  
/gene="ERBB2"  
/site\_type="glycosylation"

Bond  
Region  
Bond  
Region  
Region  
Region  
Region  
Region  
Bond  
Bond  
Region  
Site  
Region

```
/inference="non-experimental evidence, no additional details recorded"
/note="N-linked (GlcNAc...) (Potential)."
bond(531,540)
/gene="ERBB2"
/bond_type="disulfide"
/inference="non-experimental evidence, no additional details recorded"
/note="By similarity."
539..542
/gene="ERBB2"
/region_name="Beta-strand region"
/experiment="experimental evidence, no additional details recorded"
bond(544,560)
/gene="ERBB2"
/bond_type="disulfide"
/inference="non-experimental evidence, no additional details recorded"
/note="By similarity."
545..551
/gene="ERBB2"
/region_name="Beta-strand region"
/experiment="experimental evidence, no additional details recorded"
553..556
/gene="ERBB2"
/region_name="Beta-strand region"
/experiment="experimental evidence, no additional details recorded"
557..603
/gene="ERBB2"
/region_name="FU"
/note="Furin-like repeats; smart00261"
/db_xref="CDD:47590"
559..562
/gene="ERBB2"
/region_name="Beta-strand region"
/experiment="experimental evidence, no additional details recorded"
bond(563,576)
/gene="ERBB2"
/bond_type="disulfide"
/inference="non-experimental evidence, no additional details recorded"
/note="By similarity."
bond(567,584)
/gene="ERBB2"
/bond_type="disulfide"
/inference="non-experimental evidence, no additional details recorded"
/note="By similarity."
571..573
/gene="ERBB2"
/region_name="Beta-strand region"
/experiment="experimental evidence, no additional details recorded"
571
/gene="ERBB2"
/site_type="glycosylation"
/inference="non-experimental evidence, no additional details recorded"
/note="N-linked (GlcNAc...) (Potential)."
575..580
```

/gene="ERBB2"  
/region\_name="Beta-strand region"  
/experiment="experimental evidence, no additional details recorded"  
Region  
583..592  
/gene="ERBB2"  
/region\_name="Beta-strand region"  
/experiment="experimental evidence, no additional details recorded"  
Bond  
bond(587,596)  
/gene="ERBB2"  
/bond\_type="disulfide"  
/inference="non-experimental evidence, no additional details recorded"  
/note="By similarity."  
Region  
595..599  
/gene="ERBB2"  
/region\_name="Beta-strand region"  
/experiment="experimental evidence, no additional details recorded"  
Bond  
bond(600,623)  
/gene="ERBB2"  
/bond\_type="disulfide"  
/inference="non-experimental evidence, no additional details recorded"  
/note="By similarity."  
Region  
615..617  
/gene="ERBB2"  
/region\_name="Beta-strand region"  
/experiment="experimental evidence, no additional details recorded"  
Region  
621..625  
/gene="ERBB2"  
/region\_name="Beta-strand region"  
/experiment="experimental evidence, no additional details recorded"  
Bond  
bond(626,634)  
/gene="ERBB2"  
/bond\_type="disulfide"  
/inference="non-experimental evidence, no additional details recorded"  
/note="By similarity."  
Site  
629  
/gene="ERBB2"  
/site\_type="glycosylation"  
/inference="non-experimental evidence, no additional details recorded"  
/note="N-linked (GlcNAc...) (Potential)."  
Bond  
bond(630,642)  
/gene="ERBB2"  
/bond\_type="disulfide"  
/inference="non-experimental evidence, no additional details recorded"  
/note="By similarity."  
Region  
653..675  
/gene="ERBB2"  
/region\_name="Transmembrane region"  
/inference="non-experimental evidence, no additional details recorded"  
/note="Potential."  
Region  
654  
/gene="ERBB2"  
/region\_name="Variant"  
/experiment="experimental evidence, no additional details

recorded"  
/note="I -> V (in allele B3; dbSNP:rs1801201).  
/FTId=VAR\_004077."  
Region  
655  
/gene="ERBB2"  
/region\_name="Variant"  
/experiment="experimental evidence, no additional details recorded"  
/note="I -> V (in allele B2 and allele B3;  
dbSNP:rs1801200). /FTId=VAR\_004078."  
Region  
676..1255  
/gene="ERBB2"  
/region\_name="Topological domain"  
/inference="non-experimental evidence, no additional details recorded"  
/note="Cytoplasmic (Potential)."  
Region  
715..979  
/gene="ERBB2"  
/region\_name="TyrKc"  
/note="Tyrosine kinase, catalytic domain.  
Phosphotransferases; tyrosine-specific kinase subfamily;  
cd00192"  
/db\_xref="CDD:29154"  
Region  
720..987  
/gene="ERBB2"  
/region\_name="Domain"  
/experiment="experimental evidence, no additional details recorded"  
/note="Protein kinase."  
Region  
720..972  
/gene="ERBB2"  
/region\_name="S\_TKc"  
/note="Serine/Threonine protein kinases, catalytic domain;  
Phosphotransferases. Serine or threonine-specific kinase subfamily; smart00220"  
/db\_xref="CDD:47550"  
Site  
726..734  
/gene="ERBB2"  
/site\_type="np-binding"  
/inference="non-experimental evidence, no additional details recorded"  
/note="ATP (By similarity)."  
Region  
742..745  
/gene="ERBB2"  
/region\_name="Beta-strand region"  
/experiment="experimental evidence, no additional details recorded"  
Region  
748..753  
/gene="ERBB2"  
/region\_name="Beta-strand region"  
/experiment="experimental evidence, no additional details recorded"  
Site  
753  
/gene="ERBB2"  
/site\_type="binding"  
/inference="non-experimental evidence, no additional details recorded"  
/note="ATP (By similarity)."  
Region  
761..776  
/gene="ERBB2"  
/region\_name="Helical region"  
/experiment="experimental evidence, no additional details recorded"  
Site  
order(783,798..805,849..850,862..864)

Region  
785..799  
/gene="ERBB2"  
/site\_type="other"  
/note="ATP binding pocket"  
/db\_xref="CDD:29154"

Region  
806..812  
/gene="ERBB2"  
/region\_name="Beta-strand region"  
/experiment="experimental evidence, no additional details recorded"

Site  
order(807,845,849,882..886)  
/gene="ERBB2"  
/site\_type="other"  
/note="peptide substrate binding pocket"  
/db\_xref="CDD:29154"

Region  
814..816  
/gene="ERBB2"  
/region\_name="Helical region"  
/experiment="experimental evidence, no additional details recorded"

Region  
819..838  
/gene="ERBB2"  
/region\_name="Helical region"  
/experiment="experimental evidence, no additional details recorded"

Site  
843..852  
/gene="ERBB2"  
/site\_type="other"  
/note="catalytic loop"  
/db\_xref="CDD:29154"

Site  
845  
/gene="ERBB2"  
/site\_type="active"  
/inference="non-experimental evidence, no additional details recorded"  
/note="Proton acceptor (By similarity)."

Region  
848..850  
/gene="ERBB2"  
/region\_name="Helical region"  
/experiment="experimental evidence, no additional details recorded"

Region  
851..855  
/gene="ERBB2"  
/region\_name="Beta-strand region"  
/experiment="experimental evidence, no additional details recorded"

Region  
858..861  
/gene="ERBB2"  
/region\_name="Beta-strand region"  
/experiment="experimental evidence, no additional details recorded"

Site  
order(863..868,875..879,882..892)  
/gene="ERBB2"  
/site\_type="other"  
/note="activation loop"  
/db\_xref="CDD:29154"

Region  
886..888  
/gene="ERBB2"  
/region\_name="Helical region"  
/experiment="experimental evidence, no additional details recorded"

Region  
recorded"  
891..896  
/gene="ERBB2"  
/region\_name="Helical region"  
/experiment="experimental evidence, no additional details recorded"  
Region  
901..916  
/gene="ERBB2"  
/region\_name="Helical region"  
/experiment="experimental evidence, no additional details recorded"  
Region  
924..926  
/gene="ERBB2"  
/region\_name="Beta-strand region"  
/experiment="experimental evidence, no additional details recorded"  
Region  
928..930  
/gene="ERBB2"  
/region\_name="Hydrogen bonded turn"  
/experiment="experimental evidence, no additional details recorded"  
Region  
931..937  
/gene="ERBB2"  
/region\_name="Helical region"  
/experiment="experimental evidence, no additional details recorded"  
Region  
949..958  
/gene="ERBB2"  
/region\_name="Helical region"  
/experiment="experimental evidence, no additional details recorded"  
Region  
963..965  
/gene="ERBB2"  
/region\_name="Hydrogen bonded turn"  
/experiment="experimental evidence, no additional details recorded"  
Region  
969..981  
/gene="ERBB2"  
/region\_name="Helical region"  
/experiment="experimental evidence, no additional details recorded"  
Region  
983..986  
/gene="ERBB2"  
/region\_name="Helical region"  
/experiment="experimental evidence, no additional details recorded"  
Region  
1020..1022  
/gene="ERBB2"  
/region\_name="Hydrogen bonded turn"  
/experiment="experimental evidence, no additional details recorded"  
Site  
1139  
/gene="ERBB2"  
/site\_type="modified"  
/inference="non-experimental evidence, no additional details recorded"  
/note="Phosphotyrosine; by autocatalysis (By similarity)."  
Region  
1170  
/gene="ERBB2"  
/region\_name="Variant"  
/experiment="experimental evidence, no additional details recorded"  
/note="P -> A. /FTId=VAR\_016318."  
Region  
1195..1197

```

/gene="ERBB2"
/region_name="Region of interest in the sequence"
/inference="non-experimental evidence, no additional
details recorded"
/note="Interaction with PIK3C2B (Probable)."
Site
1196
/gene="ERBB2"
/site_type="modified"
/inference="non-experimental evidence, no additional
details recorded"
/note="Phosphotyrosine (Potential)."
Site
1248
/gene="ERBB2"
/site_type="modified"
/inference="non-experimental evidence, no additional
details recorded"
/note="Phosphotyrosine; by autocatalysis (By similarity)."
ORIGIN
1 melaalcrwg lllallppga astqvctgtd mklrlpaspe thldmlrhly qgcqvvqgnl
61 eltylptnas lsflqdqev qgyvliahnq vrqvplqr lr ivrgtqlfed nyalavldng
121 dplnnttpvt gaspgglrel qlrlslelk ggvliqrnpq lcyqdtlwk difhknnqla
181 ltlidtnrsr achpcspmck gsrcwgesse dcqsltrvc aggcacrkgp lptdccheqc
241 aagctgpkhs dclaclhfnh sgicelhcpa lvtyntdtfe smpnpegryt fgascvtacp
301 ynylstdvgs ctlvcplhnq evtaedgtqr cekcskpccar vcyglgmehl revravtsan
361 iqefagckki fgslaflpes fdgdpasnta plqpeqlqvf etleeitgyl yisawpdslp
421 dlsvfqnqnv irgrilhnga ysltlqqlgi swlglrsre lgsglalihh nthlcfvhtv
481 pwdqlfrnph qallhtanrp edecvgegla chqlcarghc wggpqtqcvn csqflrgqec
541 veecrvqlqgl prevnarhc lpchpecqpq ngsvtcfgpe adqcvacahy kdppfcvarc
601 psgvkpdlsy mpiwkfpdee gacqpcpinc thscvdlddk gcpaeqrasp ltsiisavvg
661 illvvvlgvv fgilikrrqq kirkytmrrl lqetelvepl tpsgampnqa qmrilketel
721 rkvkvlsgsa fgtvykgiwi pdgenvkpv aikvlrents pkankeilde ayvmagvgsp
781 yvsrllgicl tstvqlvtql mpygcldhv renrgrlgsq dllnwcmqia kgmsyledvr
841 lvhrdlaarn vlvkspnhvk itdfglarll dideteyhad ggkvpikwma lesilrrrf
901 hqsdvwsygv tvwelmtfga kpydgipare ipdllekger lpqppictid vymimvkwm
961 idsecrprfr elvsefsrma rdpqrfvviq nedlgpaspl dstfyrslle dddmgd1vda
1021 eeylpqqgf fc当地papagag gmvhhrhrss strsgggdlt lglepseeaa prsplatseg
1081 agsdvfdgdl gmgaakglqs lpthdpsplq rysetdptvpl psetdgyvap ltcspqpeyv
1141 nqpdvррр spregplaa rpagatlerp ktlspgkngv vkdvfafgga venpeyltpq
1201 ggaapqphpp pafspafdn1 yywdqdpper gappstfkgt ptaenpeylg ldvpv
//
```

[Disclaimer](#) | [Write to the Help Desk](#)  
[NCBI](#) | [NLM](#) | [NIH](#)

Jun 19 2007 13:56:00